Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rein Therapeutics Inc. (RNTX)
USD0.95
+0.04 (+4.13%)
US NASDAQ Healthcare Medical - Pharmaceuticals
Address
12407 N. Mopac Expy. 78758
Austin, TX, US
Austin, TX, US
CEO
James Brian Windsor
Website
reintx.com
IPO
2017-06-29
CIK 1420565 ISIN US00887A2042
Also trades on
NASDAQ Capital Market · ALRN (USD)
NASDAQ Global Market · RNTX (USD)
Description
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.95
+0.04 (+4.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
788.2K
Beta
1.35
Float Shares
21.35M
Free Float %
76.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.08% | -13.93% | -40.34% | -8.70% | -13.93% | -9.48% | -51.16% | -50.47% | -50.47% | -50.47% | -50.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
0.95
Low
6.00
+529.2%
Consensus
6.00
+529.2%
Median
6.00
+529.2%
High
6.00
+529.2%
DCF (Levered)
0.13
-86.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
6.00
+529.2%
|
| All Time | 1 |
6.00
+529.2%
|
Quality scores
Altman Z-Score
-23.56
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%+44.2% ★ Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%-160.1% Q1'26: -173.3% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+41.9% Q1'26: +1,285.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.00× Q1'26: -0.24× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
69.76M
69.76M – 69.76M
|
127.66M
127.66M – 127.66M
+83.0% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
144.10M
144.10M – 144.10M
|
| EBITDA |
-28.05M
|
-21.93M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-28.11M
|
-21.93M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-62.88M
est: -31.20M (-101.5%)
|
-49.87M
est: -36.77M (-35.6%)
|
-41.48M
-41.48M – -41.48M
-12.8% YoY
|
-33.84M
-33.84M – -33.84M
+18.4% YoY
|
-37.15M
-37.15M – -37.15M
-9.8% YoY
|
-31.04M
-31.04M – -31.04M
+16.4% YoY
|
10.94M
10.94M – 10.94M
+135.2% YoY
|
| SGA |
13.86M
|
10.90M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.51
est: -1.75 (-101.1%)
|
-1.96
est: -1.45 (-35.6%)
|
-1.63
-1.63 – -1.63
-12.8% YoY
|
-1.33
-1.33 – -1.33
+18.4% YoY
|
-1.46
-1.46 – -1.46
-9.8% YoY
|
-1.22
-1.22 – -1.22
+16.4% YoY
|
0.43
0.43 – 0.43
+135.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
45
Total invested
14.84M
Insider transactions (90d)
2
Beneficial owners (>5%)
35
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | The University of Texas/Texas A&M Investment Management Company | 1.81M | 6.20% | — | 1.81M | — | 1.81M | OO | TX | 2024-03-05 | ↗ |
| 2 | Muneer A. Satter | 830.5K | 4.90% | 830.5K | — | 830.5K | — | IN | — | 2024-04-16 | ↗ |
| 3 | BIOS CLINICAL OPPORTUNITY FUND, LP | 542.3K | 9.99% | — | 542.3K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 4 | BIOS EQUITY COF, LP | 542.3K | 9.99% | — | 542.3K | — | — | PN | TEXAS, UNITED STATES | 2023-11-13 | ↗ |
| 5 | BIOS EQUITY PARTNERS III, LP | 542.3K | 9.99% | — | 542.3K | — | — | PN | TEXAS, UNITED STATES | 2023-11-13 | ↗ |
| 6 | BIOS FUND III QP, LP | 542.3K | 9.99% | — | 542.3K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 7 | BIOS FUND II QP, LP | 540.4K | 9.99% | — | 540.4K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 8 | BIOS FUND I QP, LP | 540.0K | 9.99% | — | 540.0K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 9 | BIOS LTI SPV II, LP | 540.0K | 9.99% | — | 540.0K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 10 | BIOS FUND I, LP | 539.3K | 9.99% | — | 539.3K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 11 | BIOS LTI CO-INVEST III, LP | 536.2K | 9.99% | — | 536.2K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 12 | BIOS EQUITY PARTNERS, LP | 536.0K | 9.99% | — | 536.0K | — | — | PN | TEXAS, UNITED STATES | 2023-11-13 | ↗ |
| 13 | BIOS LTI CO-INVEST III QP, LP | 536.0K | 9.99% | — | 536.0K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 14 | BIOS EQUITY PARTNERS II, LP | 527.2K | 9.99% | — | 527.2K | — | — | PN | TEXAS, UNITED STATES | 2023-11-13 | ↗ |
| 15 | BIOS ADVISORS GP, LLC | 521.0K | 9.99% | — | 521.0K | — | — | OO | TEXAS, UNITED STATES | 2023-11-13 | ↗ |
| 16 | BIOS CAPITAL MANAGEMENT, LP | 521.0K | 9.99% | — | 521.0K | — | — | PN | TEXAS, UNITED STATES | 2023-11-13 | ↗ |
| 17 | CAVU ADVISORS, LLC | 521.0K | 9.99% | — | 521.0K | — | — | OO | TEXAS, UNITED STATES | 2023-11-13 | ↗ |
| 18 | CAVU MANAGEMENT, LP | 521.0K | 9.99% | — | 521.0K | — | — | PN | TEXAS, UNITED STATES | 2023-11-13 | ↗ |
| 19 | LESLIE WAYNE KREIS, JR. | 520.8K | 9.99% | 1.8K | 519.0K | 1.8K | — | IN | UNITED STATES | 2023-11-13 | ↗ |
| 20 | AARON GLEN LOUIS FLETCHER | 519.8K | 9.99% | 10.5K | 509.3K | 10.5K | — | IN | UNITED STATES | 2023-11-13 | ↗ |
| 21 | BIOS FUND II, LP | 332.3K | 6.37% | — | 332.3K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 22 | BIOS FUND III NT, LP | 187.5K | 3.70% | — | 187.5K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 23 | BIOS FUND III, LP | 178.5K | 3.52% | — | 178.5K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 24 | BIOS FUND II NT, LP | 144.4K | 2.87% | — | 144.4K | — | — | PN | DELAWARE, UNITED STATES | 2023-11-13 | ↗ |
| 25 | BVF GP Holdings LLC | — | 0.00% | — | — | — | — | OO | — | 2024-02-14 | ↗ |
| 26 | BVF I GP LLC | — | 0.00% | — | — | — | — | OO | — | 2024-02-14 | ↗ |
| 27 | BVF II GP LLC | — | 0.00% | — | — | — | — | OO | — | 2024-02-14 | ↗ |
| 28 | BVF Inc. | — | 0.00% | — | — | — | — | CO | — | 2024-02-14 | ↗ |
| 29 | BVF Partners L.P. | — | 0.00% | — | — | — | — | IA, PN | — | 2024-02-14 | ↗ |
| 30 | BVF Partners OS Ltd. | — | 0.00% | — | — | — | — | CO | — | 2024-02-14 | ↗ |
| 31 | Biotechnology Value Fund II, L.P. | — | 0.00% | — | — | — | — | PN | — | 2024-02-14 | ↗ |
| 32 | Biotechnology Value Fund, L.P. | — | 0.00% | — | — | — | — | PN | — | 2024-02-14 | ↗ |
| 33 | Biotechnology Value Trading Fund OS LP | — | 0.00% | — | — | — | — | PN | — | 2024-02-14 | ↗ |
| 34 | Mark N. Lampert | — | 0.00% | — | — | — | — | IN | — | 2024-02-14 | ↗ |
| 35 | Scott B. Kapnick | — | 0.00% | — | — | — | — | IN | United States of America | 2024-02-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
45
-1 vs prev Q
New positions
11
Closed positions
12
Increased
25
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 18.0K +18.0K (+100.0%) | 20.88M +20.9M (+100.0%) | 0.07% +0.068 pp | 0.01% +0.008 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 2 | VOSS CAPITAL, LLC | 4.24M +1.6M (+59.2%) | 4.92M +1.9M (+61.2%) | 16.10% +5.075 pp | 0.24% +0.089 pp | USD1.44 -19.4% | 5 qtrs — |
| 3 | BIOS CAPITAL MANAGEMENT, LP | 1.69M +— (+0.0%) | 1.96M +16.9K (+0.9%) | 6.41% -0.576 pp | 2.37% +0.187 pp | USD2.30 -49.6% | 5 qtrs — |
| 4 | VANGUARD GROUP INC | 1.17M -2.6K (-0.2%) | 1.35M +14.5K (+1.1%) | 4.42% -0.408 pp | 0.00% +0.000 pp | USD1.69 -31.4% | 13 qtrs — |
| 5 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | 511.6K +— (+0.0%) | 593.5K +7.7K (+1.3%) | 1.94% -0.174 pp | 0.08% -0.001 pp | USD2.12 -45.3% | 7 qtrs — |
| 6 | PROSIGHT MANAGEMENT, LP | 442.6K -125.3K (-22.1%) | 513.4K -136.8K (-21.0%) | 1.68% -0.669 pp | 0.11% -0.046 pp | USD1.88 -38.3% | 7 qtrs — |
| 7 | CABLE CAR CAPITAL LLC | 420.0K +— (+0.0%) | 487.2K +6.3K (+1.3%) | 1.59% -0.143 pp | 0.02% -0.190 pp | USD2.12 -45.3% | 7 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 284.6K +37.2K (+15.1%) | 330.2K +46.9K (+16.6%) | 1.08% +0.057 pp | 0.00% +0.000 pp | USD1.99 -41.7% | 13 qtrs — |
| 9 | TEXAS CAPITAL BANK WEALTH MANAGEMENT SERVICES INC | 262.1K +236.0K (+901.6%) | 304.1K +274.1K (+914.7%) | 0.99% +0.886 pp | 0.02% +0.015 pp | USD1.26 -7.9% | 9 qtrs — |
| 10 | SIGMA PLANNING CORP | 247.3K -6.6K (-2.6%) | 298.6K +8.0K (+2.7%) | 0.94% -0.111 pp | 0.01% +0.000 pp | USD2.05 -43.4% | 9 qtrs — |
| 11 | GAGNON SECURITIES LLC | 240.2K +11.5K (+5.0%) | 278.7K +16.8K (+6.4%) | 0.91% -0.034 pp | 0.06% +0.004 pp | USD1.44 -19.4% | 9 qtrs — |
| 12 | SENVEST MANAGEMENT, LLC | 230.9K +— (+0.0%) | 267.8K +3.5K (+1.3%) | 0.88% -0.079 pp | 0.01% 0.000 pp | USD2.12 -45.3% | 8 qtrs — |
| 13 | ABS DIRECT EQUITY FUND LLC | 125.0K +125.0K (+100.0%) | 145.0K +145.0K (+100.0%) | 0.47% +0.474 pp | 0.17% +0.173 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 14 | CITADEL ADVISORS LLC | 120.1K +91.9K (+325.8%) | 139.3K +107.0K (+331.4%) | 0.46% +0.339 pp | 0.00% +0.000 pp | USD1.22 -4.9% | 3 qtrs — |
| 15 | ROCK CREEK GROUP, LP | 100.0K +100.0K (+100.0%) | 116.0K +116.0K (+100.0%) | 0.38% +0.379 pp | 0.01% +0.013 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 16 | STATE STREET CORP | 75.9K +59.9K (+374.3%) | 88.0K +69.7K (+380.5%) | 0.29% +0.222 pp | 0.00% +0.000 pp | USD1.38 -15.9% | 7 qtrs — |
| 17 | JANE STREET GROUP, LLC | 62.0K +62.0K (+100.0%) | 71.9K +71.9K (+100.0%) | 0.24% +0.235 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 18 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 59.0K +28.1K (+91.2%) | 68.4K +33.1K (+93.7%) | 0.22% +0.096 pp | 0.00% +0.000 pp | USD1.15 +0.9% | 2 qtrs — |
| 19 | BLACKROCK, INC. | 55.0K +2.1K (+4.0%) | 63.8K +3.3K (+5.4%) | 0.21% -0.010 pp | 0.00% +0.000 pp | USD2.11 -45.0% | 6 qtrs — |
| 20 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 42.4K +— (+0.0%) | 49.2K +636.0 (+1.3%) | 0.16% -0.015 pp | 0.00% +0.000 pp | USD1.52 -23.7% | 4 qtrs — |
| 21 | TWO SIGMA INVESTMENTS, LP | 41.7K +41.7K (+100.0%) | 48.4K +48.4K (+100.0%) | 0.16% +0.158 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 22 | NORTHERN TRUST CORP | 40.5K +14.7K (+57.1%) | 46.9K +17.4K (+59.1%) | 0.15% +0.047 pp | 0.00% +0.000 pp | USD1.77 -34.5% | 7 qtrs — |
| 23 | CHICAGO PARTNERS INVESTMENT GROUP LLC | 31.0K +— (+0.0%) | 42.5K +1.6K (+3.8%) | 0.12% -0.011 pp | 0.00% +0.000 pp | USD1.72 -32.6% | 4 qtrs — |
| 24 | HRT FINANCIAL LP | 33.2K +33.2K (+100.0%) | 38.0K +38.0K (+100.0%) | 0.13% +0.126 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 25 | MERIDIAN WEALTH ADVISORS, LLC | 28.5K +— (+0.0%) | 33.0K +428.0 (+1.3%) | 0.11% -0.010 pp | 0.00% 0.000 pp | USD1.77 -34.5% | 4 qtrs — |
| 26 | RENAISSANCE TECHNOLOGIES LLC | 22.7K +4.4K (+24.1%) | 26.3K +5.4K (+25.7%) | 0.09% +0.011 pp | 0.00% +0.000 pp | USD1.15 +0.9% | 2 qtrs — |
| 27 | GLEASON GROUP, INC. | 22.4K +— (+0.0%) | 26.0K +336.0 (+1.3%) | 0.08% -0.008 pp | 0.00% +0.000 pp | USD1.40 -17.1% | 3 qtrs — |
| 28 | ANCORA ADVISORS, LLC | 20.0K +20.0K (+100.0%) | 23.2K +23.2K (+100.0%) | 0.08% +0.076 pp | 0.00% +0.001 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 29 | GLOBAL RETIREMENT PARTNERS, LLC | 19.3K +12.1K (+168.3%) | 22.4K +14.2K (+171.8%) | 0.07% +0.044 pp | 0.00% +0.000 pp | USD1.25 -7.2% | 3 qtrs — |
| 30 | KG&L CAPITAL MANAGEMENT,LLC | 18.0K +— (+0.0%) | 20.9K +270.0 (+1.3%) | 0.07% -0.006 pp | 0.01% 0.000 pp | USD2.17 -46.5% | 6 qtrs — |
| 31 | MERCER GLOBAL ADVISORS INC /ADV | 18.0K +7.5K (+71.7%) | 20.8K +8.9K (+73.9%) | 0.07% +0.025 pp | 0.00% +0.000 pp | USD1.15 +0.9% | 2 qtrs — |
| 32 | AMERICANA PARTNERS, LLC | 17.3K +— (+0.0%) | 20.1K +259.0 (+1.3%) | 0.07% -0.006 pp | 0.00% +0.000 pp | USD1.64 -29.3% | 4 qtrs — |
| 33 | TWO SIGMA SECURITIES, LLC | 17.3K +17.3K (+100.0%) | 20.0K +20.0K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.003 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 34 | ANNANDALE CAPITAL, LLC | 15.0K +15.0K (+100.0%) | 17.0K +17.0K (+100.0%) | 0.06% +0.057 pp | 0.00% +0.002 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 35 | VIRTU FINANCIAL LLC | 13.7K +13.7K (+100.0%) | 16.0K +16.0K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.001 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 36 | CETERA INVESTMENT ADVISERS | 12.4K +— (+0.0%) | 14.3K +185.0 (+1.3%) | 0.05% -0.004 pp | 0.00% +0.000 pp | USD1.40 -17.1% | 3 qtrs — |
| 37 | HIGHTOWER ADVISORS, LLC | 10.0K +10.0K (+100.0%) | 11.6K +11.6K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 38 | UBS GROUP AG | 9.5K +9.4K (+11,365.1%) | 11.0K +10.9K (+11,520.0%) | 0.04% +0.036 pp | 0.00% +0.000 pp | USD1.16 +0.0% | 13 qtrs — |
| 39 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 5.1K +— (+0.0%) | 5.9K +77.0 (+1.3%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD1.15 +0.9% | 2 qtrs — |
| 40 | NEW MILLENNIUM GROUP LLC | 2.0K +2.0K (+100.0%) | 2.4K +2.4K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.001 pp | USD1.16 +0.0% | 1 qtrs NEW |
| 41 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.0K -3.1K (-61.1%) | 2.3K -3.5K (-60.6%) | 0.01% -0.013 pp | 0.00% 0.000 pp | USD1.73 -32.9% | 13 qtrs — |
| 42 | JFS WEALTH ADVISORS, LLC | 1.6K +— (+0.0%) | 1.8K +24.0 (+1.3%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD2.12 -45.3% | 13 qtrs — |
| 43 | US BANCORP \DE\ | 1.3K +— (+0.0%) | 1.5K +19.0 (+1.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.12 -45.3% | 13 qtrs — |
| 44 | ADVISOR GROUP HOLDINGS, INC. | 70.00 +35.0 (+100.0%) | 81.00 +41.0 (+102.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.44 -19.4% | 4 qtrs — |
| 45 | BANK OF AMERICA CORP /DE/ | 42.00 -58.0 (-58.0%) | 49.00 -66.0 (-57.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.05 -43.4% | 13 qtrs — |
| 46 | RONALD BLUE TRUST, INC. | 20.00 +— (+0.0%) | 23.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.75 -33.7% | 4 qtrs — |
| 47 | BLAIR WILLIAM & CO/IL | — -23.4K (-100.0%) | — -26.8K (-100.0%) | 0.00% -0.097 pp | 0.00% 0.000 pp | USD— | 13 qtrs SOLD |
| 48 | WARBERG ASSET MANAGEMENT LLC | — -11.0K (-100.0%) | — -12.6K (-100.0%) | 0.00% -0.046 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 49 | XTX TOPCO LTD | — -15.0K (-100.0%) | — -17.2K (-100.0%) | 0.00% -0.062 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 50 | EXENCIAL WEALTH ADVISORS, LLC | — -30.5K (-100.0%) | — -35.0K (-100.0%) | 0.00% -0.126 pp | 0.00% -0.001 pp | USD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 285.5K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 4.1K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 11.2K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 825.18 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.91M | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 4.2K | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 2.3K | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 920.26 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 101.39 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 14.27 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
306.1K
Shares disposed
—
Cash buys
4.00
Cash sales
—
Net activity
+306,050
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | WINDSOR JAMES BRIAN | Director / Officer | A-Award | D | Stock Option (Right to Buy) | 150,000 | 1.17 | 175.5K | 150,000 | D | ↗ |
| 2026-04-30 | WINDSOR JAMES BRIAN | Director / Officer | P-Purchase | A | Common stock , $0.001 par value | 25,000 | 1.00 | 25.0K | 27,046 | D | ↗ |
| 2025-11-14 | Voss Capital, LP | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value | 104,183 | 1.22 | 127.6K | 926,441 | I | ↗ |
| 2025-10-28 | Voss Capital, LP | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value | 178,392 | 1.39 | 248.0K | 500,000 | I | ↗ |
| 2025-10-27 | Voss Capital, LP | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value | 4,840 | 1.37 | 6.6K | 321,608 | I | ↗ |
| 2025-10-24 | Voss Capital, LP | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value | 30,176 | 1.39 | 42.0K | 729,616 | I | ↗ |
| 2025-09-24 | Voss Capital, LP | 10% Owner | — | — | Common Stock, $0.001 par value | 0 | 0.00 | — | 316,768 | I | ↗ |
| 2025-07-23 | VON RICKENBACH JOSEF H | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 1.55 | 27.1K | 17,500 | D | ↗ |
| 2025-07-23 | Musso Alan A | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 1.55 | 27.1K | 17,500 | D | ↗ |
| 2025-07-23 | Fairey William | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 1.55 | 27.1K | 17,500 | D | ↗ |
| 2025-07-23 | Ambros Reinhard J. | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 1.55 | 27.1K | 17,500 | D | ↗ |
| 2025-07-23 | Aivado Manuel | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 1.55 | 27.1K | 17,500 | D | ↗ |
Executive team
Top executives
Shares Outstanding
28.04M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Brian Windsor | Chief Executive Officer, President & Director | 882.7K | — |
| Timothy Cunningham | Interim Chief Financial Officer & Principal Accounting Officer | 433.9K | male |
| Cory Hogaboam | Chief Scientific Officer | — | — |
| Jennifer Faigle | Counsel | — | female |
| Ron Chen | Vice President of Finance and Corporate Controller | — | male |
ESG Rating
ESG Score History MEDICAL - PHARMACEUTICALS
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RNTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
